ILCN.org (ILCN/WCLC) ILCN.org (ILCN/WCLC)
x/twitter facebook linkedin bluesky youtube instagram iaslc Home
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
Menu
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
loading...
Home Radiation Oncology

Prophylactic Radiotherapy: A Case for Patients at High Risk of Brain Metastases

Oscar Arrieta
+more
on: June 18, 2021In: Radiation Oncology
Prophylactic Radiotherapy: A Case for Patients at High Risk of Brain Metastases

Prophylactic radiotherapy for the prevention of brain metastases (Table 1) has not been considered a standard practice outside of limited stage SCLC, particularly amid the surge and approval of novel […] Read more


The Role of PORT in Patients With Completely Resected Stage III-N2 NSCLC: A Pro/Con – The Con Side

Annemarie Fernandes Shepherd
+more
on: April 22, 2021In: Radiation Oncology
The Role of PORT in Patients With Completely Resected Stage III-N2 NSCLC: A Pro/Con - The Con Side

The controversy about the role of post-operative radiation therapy (PORT) in patients with a completely resected stage III-N2 NSCLC may soon be settled with the forthcoming publication of the results of the randomized LungART trial. Study findings were presented at the 2020 European Society for Medical Oncology Annual Meeti... Read more

The Role of PORT in Patients With Completely Resected Stage III-N2 NSCLC: A Pro/Con – The Pro Side

Kristin A. Higgins
on: April 22, 2021In: Radiation Oncology
The Role of PORT in Patients With Completely Resected Stage III-N2 NSCLC: A Pro/Con - The Pro Side

The controversy about the role of post-operative radiation therapy (PORT) in patients with a completely resected stage III-N2 NSCLC may soon be settled with the forthcoming publication of the results of the randomized LungART trial. Study findings were presented at the 2020 European Society for Medical Oncology Annual Meeti... Read more

Deeper Dive Toxicity of Lung SBRT and Concurrent Immunotherapy Combinations: What We Know and What We Still Need to Learn

Sibo Tian, MD
+more
on: April 08, 2021In: Radiation Oncology
Deeper Dive Toxicity of Lung SBRT and Concurrent Immunotherapy Combinations: What We Know and What We
            Still Need to Learn

In Reference To: Tian S, Switchenko JM, Buchwald ZS, et al. Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis. Int J Radiat Oncol Biol Phys. 2020;108(1):304-313. Read more

The Dandelion Dilemma of Brain Metastases: Treating the Whole Lawn or the Weeds Separately

Hina Saeed, MD
+more
on: March 11, 2021In: Radiation Oncology
The Dandelion Dilemma of Brain Metastases: Treating the Whole Lawn or the Weeds Separately

Approximately, 40% to 60% of patients with small cell lung cancer (SCLC) develop brain metastases (BMs),1 ,2 ,3 and fewer than 15% survive beyond 2 years.4 ,5  Whereas upfront stereotactic […] Read more

PET vs. CT in Lung Cancer Surveillance: The ‘Pro’ Side from the Nuclear Medicine Perspective

Asha Kandathil, MD
on: February 27, 2021In: Radiation Oncology
PET vs. CT in Lung Cancer Surveillance: The ‘Pro’ Side from the Nuclear Medicine
            Perspective

A significant proportion of patients with stage I to III NSCLC or SCLC will have locoregional or distant metastases following curative-intent therapy. Studies have reported local recurrence rates of 22% […] Read more

Patient Perspectives on CT and PET Scans: Imaging Technology Provides Different Benefits, Drawbacks for Each Individual Patient

Ivy Elkins, MBA
+more
on: February 26, 2021In: Radiation Oncology
Patient Perspectives on CT and PET Scans: Imaging Technology Provides Different Benefits, Drawbacks for
            Each Individual Patient

For patients with metastatic lung cancer, frequent scans are a stark reality of living with cancer. Although most scans happen every 3 months, some clinical trials require scans more often […] Read more

FDG PET–CT Versus CT for Lung Cancer Surveillance: The "Con" Side

Palmi Shah, MD
on: February 25, 2021In: Radiation Oncology
FDG PET–CT Versus CT for Lung Cancer Surveillance: The "Con" Side

Lung cancer remains the leading cause of cancer-related deaths.1 Advances in early detection of lung cancer following the implementation of screening programs and the availability of newer therapies have increased […] Read more

SBRT Versus Surgery in the COVID-19 Era: What Has Changed and What Hasn't?

Suresh Senan, MRCP, FRCR, PhD
on: December 30, 2020In: Radiation Oncology
SBRT Versus Surgery in the COVID-19 Era: What Has Changed and What Hasn't?

Surgery is considered the preferred treatment in patients with lung cancer who are fit to undergo the procedure. Stereotactic radiotherapy (SBRT) is guideline recommended for patients who are unfit for […] Read more

Questions Remain Following Long-Term Results of the Phase II SABR-COMET Trial 

Ricardo Sales dos Santos, MD, PhD
on: November 23, 2020In: Radiation Oncology
Questions Remain Following Long-Term Results of the Phase II SABR-COMET Trial 

In Response To: Palma DA, Olson R, Harrow, S, et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. […] Read more

12345

SEARCH ILCN

Archives

PROVIDER RESOURCES

MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC

INDUSTRY SUPPORTED


COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events

INDUSTRY SUPPORTED

POPULAR ARTICLES

Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
IASLC Logo
ILCN Editorial Group    IASLC.org   

Advertise with Us   

© 2024 IASLC. All Rights Reserved. Powered By TriStar Event Media, LLC   Privacy Policy